<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes</journal-id><journal-id journal-id-type="hwp">diabetes</journal-id><journal-id journal-id-type="pmc">diabetes</journal-id><journal-id journal-id-type="publisher-id">Diabetes</journal-id><journal-title-group><journal-title>Diabetes</journal-title></journal-title-group><issn pub-type="ppub">0012-1797</issn><issn pub-type="epub">1939-327X</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22688337</article-id><article-id pub-id-type="pmc">3425422</article-id><article-id pub-id-type="publisher-id">1806</article-id><article-id pub-id-type="doi">10.2337/db11-1806</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology and Therapeutics</subject></subj-group></article-categories><title-group><article-title>Postprandial Platelet Activation Is Related to Postprandial Plasma Insulin Rather Than Glucose in Patients With Type 2 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Spectre</surname><given-names>Galia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Östenson</surname><given-names>Claes-Göran</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Nailin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hjemdahl</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><aff id="aff1"><sup>1</sup>Department of Medicine Solna, Clinical Pharmacology Unit, Karolinska University Hospital-Solna, Stockholm, Sweden</aff><aff id="aff2"><sup>2</sup>Department of Hematology, Coagulation Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel</aff><aff id="aff3"><sup>3</sup>Department of Molecular Medicine and Surgery, Endocrinology &amp; Diabetology Unit, Karolinska Institutet, Karolinska University Hospital-Solna, Stockholm, Sweden</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Paul Hjemdahl, <email>paul.hjemdahl@ki.se</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>17</day><month>8</month><year>2012</year></pub-date><volume>61</volume><issue>9</issue><fpage>2380</fpage><lpage>2384</lpage><history><date date-type="received"><day>09</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2012</year></date></history><permissions><copyright-statement>© 2012 by the American Diabetes Association.</copyright-statement><copyright-year>2012</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="2380.pdf"></self-uri><abstract><sec id="s1"><title></title><p><offsets xml_i="3711" xml_f="5179" txt_i="12" txt_f="1480">Postprandial hyperglycemia is associated with platelet activation. We thus investigated if meal-induced platelet activation could be attenuated by meal insulin. A randomized, double-blind, cross-over study was performed to compare postprandial platelet activation after premeal injections of placebo or insulin aspart (0.1 and 0.2 units/kg) in 18 patients with type 2 diabetes mellitus (T2DM). Platelet activation was assessed by flow cytometry, without and with stimulation by the thromboxane analog U46619 or ADP. Measurements were before and after premeal blood glucose standardization (to 6–7 mmol/L by insulin infusion, if needed) and at 90 min after the meal. Premeal insulin reduced postprandial hyperglycemia by 2–3 mmol/L compared with placebo. Postmeal insulin levels were doubled with placebo and further elevated with insulin injections. The standardized meal enhanced U46619-induced platelet P-selectin expression by 23% after placebo; this response was more than doubled after premeal insulin. U46619-induced fibrinogen binding was unchanged after meal intake with placebo but was markedly enhanced (by ∼50–60%) after premeal insulin. Postprandial platelet activation correlated positively to postprandial insulin levels and inversely to glucose levels. Premeal insulin infusion was also associated with platelet activation. Our results suggest that postprandial insulin rather than glucose accounts for postprandial platelet activation in T2DM patients.</offsets></p></sec></abstract></article-meta></front><body><p><offsets xml_i="5232" xml_f="5369" txt_i="1489" txt_f="1626">Postprandial hyperglycemia (PPH) is thought to be an independent risk factor for cardiovascular complications in diabetes mellitus (DM) (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5400" xml_f="5401" txt_i="1626" txt_f="1627">1</offsets></xref><offsets xml_i="5408" xml_f="5462" txt_i="1627" txt_f="1681">). PPH is associated with increased oxidative stress (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5493" xml_f="5494" txt_i="1681" txt_f="1682">2</offsets></xref><offsets xml_i="5501" xml_f="5529" txt_i="1682" txt_f="1710">), endothelial dysfunction (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5560" xml_f="5561" txt_i="1710" txt_f="1711">3</offsets></xref><offsets xml_i="5568" xml_f="5596" txt_i="1711" txt_f="1739">), and platelet activation (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5627" xml_f="5628" txt_i="1739" txt_f="1740">4</offsets></xref><offsets xml_i="5635" xml_f="5636" txt_i="1740" txt_f="1741">–</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5667" xml_f="5668" txt_i="1741" txt_f="1742">6</offsets></xref><offsets xml_i="5675" xml_f="5756" txt_i="1742" txt_f="1823">). In addition, control of PPH is essential to achieve the recommended target HbA</offsets><sub><offsets xml_i="5761" xml_f="5763" txt_i="1823" txt_f="1825">1c</offsets></sub><offsets xml_i="5769" xml_f="5778" txt_i="1825" txt_f="1834"> levels (</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5809" xml_f="5810" txt_i="1834" txt_f="1835">7</offsets></xref><offsets xml_i="5817" xml_f="5819" txt_i="1835" txt_f="1837">).</offsets></p><p><offsets xml_i="5826" xml_f="5879" txt_i="1838" txt_f="1891">Several new drugs targeting PPH have been developed (</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5910" xml_f="5911" txt_i="1891" txt_f="1892">1</offsets></xref><offsets xml_i="5918" xml_f="6025" txt_i="1892" txt_f="1999">), including the rapidly acting insulins. Insulin aspart reduces PPH and improves endothelial dysfunction (</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6056" xml_f="6057" txt_i="1999" txt_f="2000">3</offsets></xref><offsets xml_i="6064" xml_f="6195" txt_i="2000" txt_f="2131">). We have found that a carbohydrate-rich meal increases platelet activation and platelet–leukocyte conjugation stimulated by ADP (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6226" xml_f="6227" txt_i="2131" txt_f="2132">4</offsets></xref><offsets xml_i="6234" xml_f="6273" txt_i="2132" txt_f="2171">) and, in particular, the thromboxane A</offsets><sub><offsets xml_i="6278" xml_f="6279" txt_i="2171" txt_f="2172">2</offsets></sub><offsets xml_i="6285" xml_f="6301" txt_i="2172" txt_f="2188"> analog U46619 (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6332" xml_f="6333" txt_i="2188" txt_f="2189">5</offsets></xref><offsets xml_i="6340" xml_f="6469" txt_i="2189" txt_f="2318">) in type 2 DM (T2DM). Because healthy control subjects developed neither PPH nor increased platelet reactivity after this meal (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6500" xml_f="6501" txt_i="2318" txt_f="2319">5</offsets></xref><offsets xml_i="6508" xml_f="6735" txt_i="2319" txt_f="2546">), we hypothesized that the postprandial platelet hyperactivity was related to the hyperglycemia. Treatment with repaglinide or glibenclamide reduced PPH only mildly and did not counteract the postprandial platelet activation (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6766" xml_f="6767" txt_i="2546" txt_f="2547">4</offsets></xref><offsets xml_i="6774" xml_f="6775" txt_i="2547" txt_f="2548">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6806" xml_f="6807" txt_i="2548" txt_f="2549">5</offsets></xref><offsets xml_i="6814" xml_f="6816" txt_i="2549" txt_f="2551">).</offsets></p><p><offsets xml_i="6823" xml_f="7020" txt_i="2552" txt_f="2749">The current study was designed to evaluate if platelet activation after a carbohydrate-rich meal is related to the PPH and thus can be attenuated by premeal insulin treatment in patients with T2DM.</offsets></p><sec id="s2"><title><offsets xml_i="7044" xml_f="7071" txt_i="2750" txt_f="2777">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="7082" xml_f="7600" txt_i="2778" txt_f="3296">The study was a randomized, double-blind, cross-over study comparing postprandial platelet activation after three premeal treatments: placebo (saline) or either of two doses of subcutaneous insulin aspart (Novorapid, Novo Nordisk, Bagsvaerd, Denmark), 0.1 or 0.2 units/kg body weight. The study was performed according to good clinical practice rules and was approved by the regional ethical review board and the Swedish Medical Products Agency (EudraCT No. 2006-007031-27). All patients gave written informed consent.</offsets></p><sec id="s3"><title><offsets xml_i="7624" xml_f="7633" txt_i="3297" txt_f="3306">Patients.</offsets></title><p><offsets xml_i="7644" xml_f="7786" txt_i="3307" txt_f="3449">T2DM patients were eligible if younger than age 70 years, without known cardiovascular disease, and treated with insulin and/or metformin. HbA</offsets><sub><offsets xml_i="7791" xml_f="7793" txt_i="3449" txt_f="3451">1c</offsets></sub><offsets xml_i="7799" xml_f="8107" txt_i="3451" txt_f="3759"> levels were between 52 and 83 mmol/mol (6.9–9.7% by the Diabetes Control and Complications Trial method or 6–9% by the Mono-S method) Exclusion criteria were contraindication to insulin, acute or chronic kidney or liver diseases, or treatment with sulfonylurea, glitazones, antiplatelets, or anticoagulants.</offsets></p></sec><sec id="s4"><title><offsets xml_i="8137" xml_f="8150" txt_i="3761" txt_f="3774">Study design.</offsets></title><p><offsets xml_i="8161" xml_f="9319" txt_i="3775" txt_f="4933">Each patient participated in the study on three occasions separated by at least 2 weeks. Patients were instructed to abstain from food, tobacco, or nicotine on days of the experiment. No blood glucose–lowering medication was given in the mornings before experiments. The basal insulin dose was halved the evening before to minimize the risk of hypoglycemia. Patients arrived in the morning and rested in a semireclining position for 30 min, after which baseline blood samples (baseline 1 [B1]) were drawn for platelet function, glucose, and insulin levels. Premeal blood glucose levels were “standardized” to 6–7 mmol/L on every occasion by intravenous infusion of insulin aspart, if needed. A second set of blood tests was taken (baseline 2 [B2]) 15 min after the target premeal glucose level was achieved. Patients who already had glucose below 7 mmol/L at B1 rested 45 min before B2 measurements. After B2 sampling, one of the three treatments—insulin aspart at 0.1 or 0.2 units/kg body weight or placebo (in a randomized order)—was injected subcutaneously immediately before the standardized meal (54% carbohydrates, 30% fat, and 16% protein, 620 kcal) (</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="9350" xml_f="9351" txt_i="4933" txt_f="4934">4</offsets></xref><offsets xml_i="9358" xml_f="9359" txt_i="4934" txt_f="4935">,</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9390" xml_f="9391" txt_i="4935" txt_f="4936">5</offsets></xref><offsets xml_i="9398" xml_f="9506" txt_i="4936" txt_f="5044">) was ingested during a 15-min period. Patients rested another 90 min before the postprandial (PP) sampling.</offsets></p></sec><sec id="s5"><title><offsets xml_i="9536" xml_f="9548" txt_i="5046" txt_f="5058">Blood tests.</offsets></title><p><offsets xml_i="9559" xml_f="9859" txt_i="5059" txt_f="5359">At B1, after premeal glucose titration (B2), and 90 min after the meal (PP), a complete blood cell count, triglyceride levels, and platelet activation measurements were taken. Plasma glucose (glucose oxidase technique; Hemocue Glucose 201+, Hemocue AB, Ängelholm, Sweden), insulin (radioimmunoassay [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9890" xml_f="9891" txt_i="5359" txt_f="5360">6</offsets></xref><offsets xml_i="9898" xml_f="10015" txt_i="5360" txt_f="5477">]), and C-peptide (Human C-Peptide RIA, Millipore, Billerica, MA) were measured before and repeatedly after the meal.</offsets></p></sec><sec id="s6"><title><offsets xml_i="10045" xml_f="10060" txt_i="5479" txt_f="5494">Flow cytometry.</offsets></title><p><offsets xml_i="10071" xml_f="10170" txt_i="5495" txt_f="5594">Platelet P-selectin expression and fibrinogen binding were measured by whole blood flow cytometry (</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="10201" xml_f="10202" txt_i="5594" txt_f="5595">8</offsets></xref><offsets xml_i="10209" xml_f="10210" txt_i="5595" txt_f="5596">,</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="10241" xml_f="10242" txt_i="5596" txt_f="5597">9</offsets></xref><offsets xml_i="10249" xml_f="10373" txt_i="5597" txt_f="5721">) and are reported as percentages of positive cells in the platelet population. Platelet agonists were U46619 (thromboxane A</offsets><sub><offsets xml_i="10378" xml_f="10379" txt_i="5721" txt_f="5722">2</offsets></sub><offsets xml_i="10385" xml_f="10526" txt_i="5722" txt_f="5863"> analog, 0.3 μmol/L), ADP (1 μmol/L), and a collagen-related peptide (CRP-18/i; 0.3 µg/mL), which activates platelet glycoprotein VI (GPVI) (</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10558" xml_f="10560" txt_i="5863" txt_f="5865">10</offsets></xref><offsets xml_i="10567" xml_f="10569" txt_i="5865" txt_f="5867">).</offsets></p></sec><sec id="s7"><title><offsets xml_i="10599" xml_f="10610" txt_i="5869" txt_f="5880">Statistics.</offsets></title><p><offsets xml_i="10621" xml_f="10808" txt_i="5881" txt_f="6068">Continuous data were compared by repeated-measures ANOVA, with Fisher post hoc testing to control for multiplicity. Differences between two treatments were analyzed by the Student paired </offsets><italic><offsets xml_i="10816" xml_f="10817" txt_i="6068" txt_f="6069">t</offsets></italic><offsets xml_i="10826" xml_f="11246" txt_i="6069" txt_f="6489"> test after validation for normal distribution (Shapiro-Wilk test). Wilcoxon matched pairs test was used for skewed variables. The Pearson correlation coefficient was used to test independence between variables. Trend analyses were performed by means of regression analysis. Mean values and SDs are given unless otherwise specified. Analyses were done using STATISTICA 7 software (StatSoft, Tulsa, OK), and probability (</offsets><italic><offsets xml_i="11254" xml_f="11255" txt_i="6489" txt_f="6490">P</offsets></italic><offsets xml_i="11264" xml_f="11283" txt_i="6490" txt_f="6509">) values are given.</offsets></p><p><offsets xml_i="11290" xml_f="11746" txt_i="6510" txt_f="6966">We estimated that 15 subjects were required to detect a 20% effect of interventions at the 5% level of significance using ADP-induced platelet P-selectin expression. When stimulated by 0.3 μmol/L U46619, the percentage of P-selectin–positive platelets increased by 9.66% (Δ value) after the meal in ref. 5. Assuming an SD of 6.63 for a 50% reduction of this Δ value, we would need 15 patients to achieve the desired statistical power (α = 0.05; 1−β = 0.8).</offsets></p></sec></sec><sec sec-type="results" id="s8"><title><offsets xml_i="11801" xml_f="11808" txt_i="6969" txt_f="6976">RESULTS</offsets></title><sec id="s9"><title><offsets xml_i="11836" xml_f="11845" txt_i="6977" txt_f="6986">Patients.</offsets></title><p><offsets xml_i="11856" xml_f="11945" txt_i="6987" txt_f="7076">Of 27 screened patients, 18 were enrolled. Reasons for exclusion were failure to meet HbA</offsets><sub><offsets xml_i="11950" xml_f="11952" txt_i="7076" txt_f="7078">1c</offsets></sub><offsets xml_i="11958" xml_f="12146" txt_i="7078" txt_f="7266"> criteria, anticoagulant treatment, thrombocytopenia, or technically suboptimal venipunctures. One patient withdrew consent after the first visit. Patient characteristics are presented in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="12178" xml_f="12185" txt_i="7266" txt_f="7273">Table 1</offsets></xref><offsets xml_i="12192" xml_f="12193" txt_i="7273" txt_f="7274">.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="12241" xml_f="12248" txt_i="7275" txt_f="7282">TABLE 1</offsets></label><caption><p><offsets xml_i="12268" xml_f="12291" txt_i="7282" txt_f="7305">Patient characteristics</offsets></p></caption><graphic xlink:href="2380tbl1"></graphic></table-wrap></sec><sec id="s10"><title><offsets xml_i="12386" xml_f="12425" txt_i="7307" txt_f="7346">Glucose, insulin, and C-peptide levels.</offsets></title><p><offsets xml_i="12436" xml_f="12534" txt_i="7347" txt_f="7445">Basal fasting levels (B1) of glucose, insulin, and C-peptide were similar on the three occasions (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12564" xml_f="12570" txt_i="7445" txt_f="7451">Fig. 1</offsets></xref><offsets xml_i="12577" xml_f="12579" txt_i="7451" txt_f="7453">, </offsets><xref ref-type="table" rid="T2"><offsets xml_i="12611" xml_f="12618" txt_i="7453" txt_f="7460">Table 2</offsets></xref><offsets xml_i="12625" xml_f="13003" txt_i="7460" txt_f="7838">). Insulin infusion was needed in 16 patients on 43 occasions to reduce premeal glucose to 6–7 mmol/L; 2 patients needed no insulin. After the glucose standardization procedure (B2), insulin levels increased, and glucose and C-peptide levels decreased compared with B1. Premeal glucose, insulin, and C-peptide levels at B2 were very similar on the three experimental occasions (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13033" xml_f="13039" txt_i="7838" txt_f="7844">Fig. 1</offsets></xref><offsets xml_i="13046" xml_f="13048" txt_i="7844" txt_f="7846">, </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13080" xml_f="13087" txt_i="7846" txt_f="7853">Table 2</offsets></xref><offsets xml_i="13094" xml_f="13096" txt_i="7853" txt_f="7855">).</offsets></p><fig id="F1" fig-type="figure" position="float"><label><offsets xml_i="13155" xml_f="13162" txt_i="7856" txt_f="7863">FIG. 1.</offsets></label><caption><p><offsets xml_i="13182" xml_f="13221" txt_i="7863" txt_f="7902">Concentrations for plasma (P) glucose (</offsets><italic><offsets xml_i="13229" xml_f="13230" txt_i="7902" txt_f="7903">A</offsets></italic><offsets xml_i="13239" xml_f="13251" txt_i="7903" txt_f="7915">), insulin (</offsets><italic><offsets xml_i="13259" xml_f="13260" txt_i="7915" txt_f="7916">B</offsets></italic><offsets xml_i="13269" xml_f="13287" txt_i="7916" txt_f="7934">), and C-peptide (</offsets><italic><offsets xml_i="13295" xml_f="13296" txt_i="7934" txt_f="7935">C</offsets></italic><offsets xml_i="13305" xml_f="13781" txt_i="7935" txt_f="8411">) are shown on the three experimental occasions. Measurements were performed before (B1) and after (B2) blood glucose standardization (by insulin infusion, if needed) to 6–7 mmol/L before the experimental treatment and meal intake. Measurements after the meal were as indicated, with the last measurement after 90 min (PP). Premeal treatments were placebo (solid lines) and insulin aspart at 0.1 units/kg (dashed lines) and at 0.2 units/kg (dotted lines). For statistics, see </offsets><xref ref-type="table" rid="T2"><offsets xml_i="13813" xml_f="13820" txt_i="8411" txt_f="8418">Table 2</offsets></xref><offsets xml_i="13827" xml_f="13832" txt_i="8418" txt_f="8423"> and </offsets><sc><offsets xml_i="13836" xml_f="13843" txt_i="8423" txt_f="8430">results</offsets></sc><offsets xml_i="13848" xml_f="13897" txt_i="8430" txt_f="8479">. Mean values and SEM are shown from 18 patients.</offsets></p></caption><graphic xlink:href="2380fig1"></graphic></fig><table-wrap id="T2" position="float"><label><offsets xml_i="14002" xml_f="14009" txt_i="8480" txt_f="8487">TABLE 2</offsets></label><caption><p><offsets xml_i="14029" xml_f="14067" txt_i="8487" txt_f="8525">Glucose, insulin, and C-peptide levels</offsets></p></caption><graphic xlink:href="2380tbl2"></graphic></table-wrap><p><offsets xml_i="14138" xml_f="14249" txt_i="8526" txt_f="8637">Premeal insulin reduced postprandial plasma glucose significantly (by 2–3 mmol/L at PP) compared with placebo (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14279" xml_f="14285" txt_i="8637" txt_f="8643">Fig. 1</offsets></xref><offsets xml_i="14292" xml_f="14349" txt_i="8643" txt_f="8700">), but the difference between doses was not significant (</offsets><italic><offsets xml_i="14357" xml_f="14358" txt_i="8700" txt_f="8701">P</offsets></italic><offsets xml_i="14367" xml_f="14608" txt_i="8701" txt_f="8942"> = 0.16). Postprandial plasma insulin increased with placebo (representing endogenous insulin secretion) and was further increased after premeal injections of insulin aspart. Maximal levels of insulin were achieved 30–60 min after the meal (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14638" xml_f="14644" txt_i="8942" txt_f="8948">Fig. 1</offsets></xref><offsets xml_i="14651" xml_f="14761" txt_i="8948" txt_f="9058">); 90 min after the meal (PP), plasma insulin was higher after 0.2 compared with 0.1 units/kg insulin aspart (</offsets><italic><offsets xml_i="14769" xml_f="14770" txt_i="9058" txt_f="9059">P</offsets></italic><offsets xml_i="14779" xml_f="14889" txt_i="9059" txt_f="9169"> = 0.004). Postprandial C-peptide levels increased after the meal, with the greatest increment after placebo (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14919" xml_f="14925" txt_i="9169" txt_f="9175">Fig. 1</offsets></xref><offsets xml_i="14932" xml_f="14934" txt_i="9175" txt_f="9177">, </offsets><xref ref-type="table" rid="T2"><offsets xml_i="14966" xml_f="14973" txt_i="9177" txt_f="9184">Table 2</offsets></xref><offsets xml_i="14980" xml_f="14982" txt_i="9184" txt_f="9186">).</offsets></p></sec><sec id="s11"><title><offsets xml_i="15013" xml_f="15056" txt_i="9188" txt_f="9231">Platelet activation after insulin infusion.</offsets></title><p><offsets xml_i="15067" xml_f="15445" txt_i="9232" txt_f="9610">Six patients did not require insulin infusion on 11 different occasions (B1 glucose was below 7 mmol/L); these occasions were not included in this analysis. Significant platelet activation occurred after intravenous insulin infusion on 43 occasions. P-selectin–positive platelets were mildly but significantly enhanced by 10% in unstimulated blood (from 2.3 ± 0.6 to 2.6 ± 0.7; </offsets><italic><offsets xml_i="15453" xml_f="15454" txt_i="9610" txt_f="9611">P</offsets></italic><offsets xml_i="15463" xml_f="15543" txt_i="9611" txt_f="9691"> = 0.005) and by 7.5% in ADP-stimulated samples (from 56.3 ± 8.0 to 60.6 ± 8.5; </offsets><italic><offsets xml_i="15551" xml_f="15552" txt_i="9691" txt_f="9692">P</offsets></italic><offsets xml_i="15561" xml_f="15662" txt_i="9692" txt_f="9790"> &lt; 0.001), whereas marked enhancement was seen with U46619 (67%, from 19.1 ± 13.7 to 31.7 ± 22.1; </offsets><italic><offsets xml_i="15670" xml_f="15671" txt_i="9790" txt_f="9791">P</offsets></italic><offsets xml_i="15680" xml_f="15693" txt_i="9791" txt_f="9801"> &lt; 0.001).</offsets></p></sec><sec id="s12"><title><offsets xml_i="15724" xml_f="15759" txt_i="9803" txt_f="9838">Platelet activation after the meal.</offsets></title><p><offsets xml_i="15770" xml_f="15880" txt_i="9839" txt_f="9949">Platelet activation was enhanced 90 min after the meal (PP), most markedly in response to U46619 stimulation (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="15910" xml_f="15916" txt_i="9949" txt_f="9955">Fig. 2</offsets></xref><offsets xml_i="15923" xml_f="16056" txt_i="9955" txt_f="10088">). Modest but significant meal effects on platelet P-selectin expression were also found in unstimulated and ADP-stimulated samples (</offsets><italic><offsets xml_i="16064" xml_f="16065" txt_i="10088" txt_f="10089">P</offsets></italic><offsets xml_i="16074" xml_f="16087" txt_i="10089" txt_f="10102"> = 0.006 and </offsets><italic><offsets xml_i="16095" xml_f="16096" txt_i="10102" txt_f="10103">P</offsets></italic><offsets xml_i="16105" xml_f="16500" txt_i="10103" txt_f="10495"> &lt; 0.001, respectively, in the overall ANOVAs). Thus, ADP increased P-selectin expression from 2.3 ± 0.7% to 56.2 ± 8.0% at baseline and from 2.5 ± 0.6% to 62.4 ± 8.1% after the meal on the placebo occasion. GPVI stimulation increased P-selectin expression to ∼30% and fibrinogen binding to ∼20% on all occasions (i.e., without effects of meal intake or insulin treatment, results not shown).</offsets></p><fig id="F2" fig-type="figure" position="float"><label><offsets xml_i="16559" xml_f="16566" txt_i="10496" txt_f="10503">FIG. 2.</offsets></label><caption><p><offsets xml_i="16586" xml_f="16618" txt_i="10503" txt_f="10535">Platelet P-selectin expression (</offsets><italic><offsets xml_i="16626" xml_f="16627" txt_i="10535" txt_f="10536">A</offsets></italic><offsets xml_i="16636" xml_f="16662" txt_i="10536" txt_f="10562">) and fibrinogen binding (</offsets><italic><offsets xml_i="16670" xml_f="16671" txt_i="10562" txt_f="10563">B</offsets></italic><offsets xml_i="16680" xml_f="16765" txt_i="10563" txt_f="10648">) expressed as the percentage of positive cells without (Rest) and with thromboxane A</offsets><sub><offsets xml_i="16770" xml_f="16771" txt_i="10648" txt_f="10649">2</offsets></sub><offsets xml_i="16777" xml_f="17076" txt_i="10649" txt_f="10948"> receptor stimulation by U46619 (0.3 µmol/L) on the three experimental occasions (i.e., with premeal injections of placebo or 0.1 or 0.2 units/kg insulin). Measurements were performed before (B1; □) and after (B2; ▨) glucose standardization, and 90 min after the meal (PP; ■). Mean values and SEM. *</offsets><italic><offsets xml_i="17084" xml_f="17085" txt_i="10948" txt_f="10949">P</offsets></italic><offsets xml_i="17094" xml_f="17108" txt_i="10949" txt_f="10960"> &lt; 0.05, **</offsets><italic><offsets xml_i="17116" xml_f="17117" txt_i="10960" txt_f="10961">P</offsets></italic><offsets xml_i="17126" xml_f="17316" txt_i="10961" txt_f="11148"> &lt; 0.01. The postprandial platelet activation responses to U46619 were significantly enhanced by meal insulin treatment in the ANOVA. Correlations are shown between postprandial glucose (</offsets><italic><offsets xml_i="17324" xml_f="17325" txt_i="11148" txt_f="11149">C</offsets></italic><offsets xml_i="17334" xml_f="17359" txt_i="11149" txt_f="11174">) and insulin responses (</offsets><italic><offsets xml_i="17367" xml_f="17368" txt_i="11174" txt_f="11175">D</offsets></italic><offsets xml_i="17377" xml_f="17814" txt_i="11175" txt_f="11612">) and platelet P-selectin responses to U46619 (PS-U) stimulation. The postprandial responses were calculated as PP-to-B2 ratios and are shown for all 18 patients on all occasions. The postprandial platelet activation correlated inversely with the postprandial glucose response and positively with the increase in plasma insulin 90 min after the meal. (A high-quality color representation of this figure is available in the online issue.)</offsets></p></caption><graphic xlink:href="2380fig2"></graphic></fig><p><offsets xml_i="17878" xml_f="18041" txt_i="11613" txt_f="11776">The following net meal effects on platelet activation (PP vs. B2) could be seen after placebo injection: U46619–stimulated P-selectin expression increased by 23% (</offsets><italic><offsets xml_i="18049" xml_f="18050" txt_i="11776" txt_f="11777">P</offsets></italic><offsets xml_i="18059" xml_f="18068" txt_i="11777" txt_f="11786"> = 0.02, </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18098" xml_f="18104" txt_i="11786" txt_f="11792">Fig. 2</offsets><italic><offsets xml_i="18112" xml_f="18113" txt_i="11792" txt_f="11793">A</offsets></italic></xref><offsets xml_i="18129" xml_f="18186" txt_i="11793" txt_f="11850">) and ADP-induced P-selectin expression increased by 5% (</offsets><italic><offsets xml_i="18194" xml_f="18195" txt_i="11850" txt_f="11851">P</offsets></italic><offsets xml_i="18204" xml_f="18365" txt_i="11851" txt_f="12012"> = 0.005, data not shown). Other measures, such as unstimulated platelet P-selectin expression and fibrinogen binding, did not increase after placebo injection (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18395" xml_f="18401" txt_i="12012" txt_f="12018">Fig. 2</offsets></xref><offsets xml_i="18408" xml_f="18410" txt_i="12018" txt_f="12020">).</offsets></p><p><offsets xml_i="18417" xml_f="18822" txt_i="12021" txt_f="12426">Postprandial platelet activation was much more consistent and pronounced after premeal insulin compared with placebo, with no significant difference between 0.1 and 0.2 units/kg insulin. There was no significant interaction term for treatment effects on platelet P-selectin expression in unstimulated or ADP-stimulated samples, but U46619-stimulated samples showed larger responses after premeal insulin (</offsets><italic><offsets xml_i="18830" xml_f="18831" txt_i="12426" txt_f="12427">P</offsets></italic><offsets xml_i="18840" xml_f="18884" txt_i="12427" txt_f="12471"> = 0.013 for interaction term in the ANOVA; </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="18914" xml_f="18920" txt_i="12471" txt_f="12477">Fig. 2</offsets><italic><offsets xml_i="18928" xml_f="18929" txt_i="12477" txt_f="12478">A</offsets></italic></xref><offsets xml_i="18945" xml_f="19001" txt_i="12478" txt_f="12534">). Postprandial P-selectin expression increased by 10% (</offsets><italic><offsets xml_i="19009" xml_f="19010" txt_i="12534" txt_f="12535">P</offsets></italic><offsets xml_i="19019" xml_f="19037" txt_i="12535" txt_f="12553"> = 0.01) and 15% (</offsets><italic><offsets xml_i="19045" xml_f="19046" txt_i="12553" txt_f="12554">P</offsets></italic><offsets xml_i="19055" xml_f="19222" txt_i="12554" txt_f="12721"> = 0.02) in unstimulated samples after premeal injections of 0.1 and 0.2 units/kg insulin, respectively. Increases were 57% and 54% in samples stimulated with U46619 (</offsets><italic><offsets xml_i="19230" xml_f="19231" txt_i="12721" txt_f="12722">P</offsets></italic><offsets xml_i="19240" xml_f="19262" txt_i="12722" txt_f="12741"> &lt; 0.001 for both; </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19292" xml_f="19298" txt_i="12741" txt_f="12747">Fig. 2</offsets><italic><offsets xml_i="19306" xml_f="19307" txt_i="12747" txt_f="12748">A</offsets></italic></xref><offsets xml_i="19323" xml_f="19333" txt_i="12748" txt_f="12758">) and 5% (</offsets><italic><offsets xml_i="19341" xml_f="19342" txt_i="12758" txt_f="12759">P</offsets></italic><offsets xml_i="19351" xml_f="19369" txt_i="12759" txt_f="12777"> = 0.006) and 9% (</offsets><italic><offsets xml_i="19377" xml_f="19378" txt_i="12777" txt_f="12778">P</offsets></italic><offsets xml_i="19387" xml_f="19426" txt_i="12778" txt_f="12814"> &lt; 0.001) with ADP (data not shown).</offsets></p><p><offsets xml_i="19433" xml_f="19680" txt_i="12815" txt_f="13062">Meal effects on platelet fibrinogen-binding were more complex: unchanged in unstimulated samples, slightly but significantly decreased with ADP-stimulation, and increased by 46–49%, on average, in U-46619-stimulated samples after premeal insulin (</offsets><italic><offsets xml_i="19688" xml_f="19689" txt_i="13062" txt_f="13063">P</offsets></italic><offsets xml_i="19698" xml_f="19738" txt_i="13063" txt_f="13103"> = 0.007 for meal effects in the ANOVA; </offsets><italic><offsets xml_i="19746" xml_f="19747" txt_i="13103" txt_f="13104">P</offsets></italic><offsets xml_i="19756" xml_f="19787" txt_i="13104" txt_f="13135"> = 0.045 for treatment effect; </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19817" xml_f="19823" txt_i="13135" txt_f="13141">Fig. 2</offsets><italic><offsets xml_i="19831" xml_f="19832" txt_i="13141" txt_f="13142">B</offsets></italic></xref><offsets xml_i="19848" xml_f="19850" txt_i="13142" txt_f="13144">).</offsets></p><p><offsets xml_i="19857" xml_f="19991" txt_i="13145" txt_f="13279">The postprandial enhancement of U46619-induced platelet P-selectin expression was inversely correlated with changes in blood glucose (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="20021" xml_f="20027" txt_i="13279" txt_f="13285">Fig. 2</offsets><italic><offsets xml_i="20035" xml_f="20036" txt_i="13285" txt_f="13286">C</offsets></italic></xref><offsets xml_i="20052" xml_f="20126" txt_i="13286" txt_f="13360">) and positively correlated with changes in plasma insulin from B2 to PP (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="20156" xml_f="20162" txt_i="13360" txt_f="13366">Fig. 2</offsets><italic><offsets xml_i="20170" xml_f="20171" txt_i="13366" txt_f="13367">D</offsets></italic></xref><offsets xml_i="20187" xml_f="20304" txt_i="13367" txt_f="13484">). Similarly, meal-induced changes in platelet fibrinogen binding tended to correlate inversely with plasma glucose (</offsets><italic><offsets xml_i="20312" xml_f="20313" txt_i="13484" txt_f="13485">P</offsets></italic><offsets xml_i="20322" xml_f="20367" txt_i="13485" txt_f="13530"> = 0.06) and positively with plasma insulin (</offsets><italic><offsets xml_i="20375" xml_f="20376" txt_i="13530" txt_f="13531">P</offsets></italic><offsets xml_i="20385" xml_f="20410" txt_i="13531" txt_f="13556"> = 0.04; data not shown).</offsets></p></sec></sec><sec sec-type="discussion" id="s13"><title><offsets xml_i="20469" xml_f="20479" txt_i="13559" txt_f="13569">DISCUSSION</offsets></title><p><offsets xml_i="20490" xml_f="21372" txt_i="13570" txt_f="14452">This study was designed to evaluate whether platelet activation after a carbohydrate-rich meal is related to the PPH. However, attenuation of PPH by premeal insulin injections did not result in reduced platelet activation. On the contrary, platelet activation evoked by thromboxane receptor stimulation (U46619) was markedly enhanced after premeal insulin, and a positive correlation was observed between postprandial platelet activation and insulin levels. In support of direct or indirect platelet activating effects of insulin in vivo, we found that insulin infusion to standardize premeal glucose levels was also associated with increased platelet reactivity. These results suggest that postprandial hyperinsulinemia, rather than PPH, causes platelet hyperactivity mediated via pathways stimulated by thromboxane and ADP but not collagen after food intake in patients with T2DM.</offsets></p><p><offsets xml_i="21379" xml_f="21526" txt_i="14453" txt_f="14600">Several studies, including work from our laboratory, have shown that high glucose can increase platelet reactivity via an elevation of osmolality (</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="21558" xml_f="21560" txt_i="14600" txt_f="14602">11</offsets></xref><offsets xml_i="21567" xml_f="21568" txt_i="14602" txt_f="14603">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="21600" xml_f="21602" txt_i="14603" txt_f="14605">12</offsets></xref><offsets xml_i="21609" xml_f="21775" txt_i="14605" txt_f="14771">). Our findings of postprandial platelet hyperreactivity in T2DM patients but not in healthy control subjects led us to propose that PPH causes platelet dysfunction (</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="21806" xml_f="21807" txt_i="14771" txt_f="14772">5</offsets></xref><offsets xml_i="21814" xml_f="21947" txt_i="14772" txt_f="14905">). In line with this notion, acarbose treatment, which attenuates PPH, reduced the urinary thromboxane metabolite excretion in T2DM (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="21978" xml_f="21979" txt_i="14905" txt_f="14906">6</offsets></xref><offsets xml_i="21986" xml_f="22071" txt_i="14906" txt_f="14991">). Our present finding challenges the concept that PPH enhances platelet activation (</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="22102" xml_f="22103" txt_i="14991" txt_f="14992">6</offsets></xref><offsets xml_i="22110" xml_f="22214" txt_i="14992" txt_f="15096">) and indicates that other mechanisms may underlie postprandial platelet hyperactivity in T2DM patients.</offsets></p><p><offsets xml_i="22221" xml_f="22303" txt_i="15097" txt_f="15179">Platelets express insulin and IGF-1 receptors, which may be activated by insulin (</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="22335" xml_f="22337" txt_i="15179" txt_f="15181">13</offsets></xref><offsets xml_i="22344" xml_f="22345" txt_i="15181" txt_f="15182">–</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="22377" xml_f="22379" txt_i="15182" txt_f="15184">15</offsets></xref><offsets xml_i="22386" xml_f="22596" txt_i="15184" txt_f="15394">), but the literature on insulin effects on platelet activation is inconsistent. We have found mild platelet-activating effects of insulin at physiologic concentrations (10–100 µU/mL [60–600 pmol/L]) in vitro (</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="22627" xml_f="22628" txt_i="15394" txt_f="15395">9</offsets></xref><offsets xml_i="22635" xml_f="22636" txt_i="15395" txt_f="15396">,</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="22668" xml_f="22670" txt_i="15396" txt_f="15398">16</offsets></xref><offsets xml_i="22677" xml_f="22845" txt_i="15398" txt_f="15566">). This is in line with the present in vivo results. However, several laboratories have found platelet-inhibiting effects of higher insulin concentrations (≥1 nmol/L) (</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="22877" xml_f="22879" txt_i="15566" txt_f="15568">14</offsets></xref><offsets xml_i="22886" xml_f="22887" txt_i="15568" txt_f="15569">,</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="22919" xml_f="22921" txt_i="15569" txt_f="15571">17</offsets></xref><offsets xml_i="22928" xml_f="22929" txt_i="15571" txt_f="15572">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="22961" xml_f="22963" txt_i="15572" txt_f="15574">19</offsets></xref><offsets xml_i="22970" xml_f="23055" txt_i="15574" txt_f="15659">), and platelet-activating effects of very high insulin concentrations (100 nmol/L) (</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="23087" xml_f="23089" txt_i="15659" txt_f="15661">15</offsets></xref><offsets xml_i="23096" xml_f="23097" txt_i="15661" txt_f="15662">,</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="23129" xml_f="23131" txt_i="15662" txt_f="15664">17</offsets></xref><offsets xml_i="23138" xml_f="23139" txt_i="15664" txt_f="15665">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="23171" xml_f="23173" txt_i="15665" txt_f="15667">19</offsets></xref><offsets xml_i="23180" xml_f="23320" txt_i="15667" txt_f="15807">). Others found no direct effects of insulin on platelets in vitro but found inhibitory effects during coincubation with endothelial cells (</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="23352" xml_f="23354" txt_i="15807" txt_f="15809">20</offsets></xref><offsets xml_i="23361" xml_f="23477" txt_i="15809" txt_f="15925">). In healthy individuals, insulin appears to suppress platelet activation through inhibition of the P2Y12 pathway (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="23509" xml_f="23511" txt_i="15925" txt_f="15927">18</offsets></xref><offsets xml_i="23518" xml_f="23676" txt_i="15927" txt_f="16085">). However, patients with T2DM and even obese insulin-resistant subjects seem to have “platelet insulin resistance” and lose their responsiveness to insulin (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="23708" xml_f="23710" txt_i="16085" txt_f="16087">18</offsets></xref><offsets xml_i="23717" xml_f="23718" txt_i="16087" txt_f="16088">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="23750" xml_f="23752" txt_i="16088" txt_f="16090">21</offsets></xref><offsets xml_i="23759" xml_f="23760" txt_i="16090" txt_f="16091">,</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="23792" xml_f="23794" txt_i="16091" txt_f="16093">22</offsets></xref><offsets xml_i="23801" xml_f="23971" txt_i="16093" txt_f="16263">). In insulin-treated obese T2DM patients, there are increases in collagen- and ADP-induced platelet adhesion and aggregation, and increased phosphatidylserine exposure (</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="24003" xml_f="24005" txt_i="16263" txt_f="16265">18</offsets></xref><offsets xml_i="24012" xml_f="24057" txt_i="16265" txt_f="16310">), which is consistent with our observations.</offsets></p><p><offsets xml_i="24064" xml_f="24487" txt_i="16311" txt_f="16734">In the second Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 2) study, insulin treatment of T2DM patients after a myocardial infarction was associated with an increased risk of myocardial infarction or stroke compared with sulfonylurea treatment, whereas metformin treatment, which increases insulin sensitivity, was associated with a decreased risk compared with sulfonylurea treatment (</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="24519" xml_f="24521" txt_i="16734" txt_f="16736">23</offsets></xref><offsets xml_i="24528" xml_f="24804" txt_i="16736" txt_f="17012">). Our findings of platelet activation by insulin in vivo may be relevant in this context. Also of interest are findings of higher platelet activity among T2DM patients receiving dual-antiplatelet treatment who were also treated with insulin compared with those who were not (</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="24836" xml_f="24838" txt_i="17012" txt_f="17014">24</offsets></xref><offsets xml_i="24845" xml_f="25025" txt_i="17014" txt_f="17194">). The importance of insulin resistance for these findings in T2DM patients and the mechanisms involved in the presently observed meal effects, such as increased oxidative stress (</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="25056" xml_f="25057" txt_i="17194" txt_f="17195">2</offsets></xref><offsets xml_i="25064" xml_f="25097" txt_i="17195" txt_f="17228">), deserve further investigation.</offsets></p><p><offsets xml_i="25104" xml_f="25266" txt_i="17229" txt_f="17391">In conclusion, our results suggest that postprandial insulin rather than glucose levels may account for meal-induced platelet hyperactivity in patients with T2DM.</offsets></p></sec></body><back><fn-group><fn id="fn1"><p>Clinical trial reg. no. NCT00771693, <ext-link ext-link-type="uri" xlink:href="clinicaltrials.gov">clinicaltrials.gov</ext-link>.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>This work was supported by grants from the Swedish Research Council/Medicine, the Swedish Heart-Lung Foundation, Karolinska Institutet, and the Stockholm County Council.</p><p>Novo Nordisk AB kindly provided a research grant for partial support of the study, which was academically initiated and conducted. No other potential conflicts of interest relevant to this article were reported.</p><p>G.S. designed the research, researched and analyzed the data, and wrote the manuscript. C.-G.Ö. and N.L. designed the research and revised the manuscript. P.H. designed the research, analyzed the data, and wrote the manuscript. P.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p>This work was presented as a poster at the XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Kyoto, Japan, 23–28 July 2011. The abstract is published in J Thromb Haemost 2011;9(Suppl. 2):344.</p><p>The authors thank Maud Daleskog, Maj-Christina Johansson, Kathinka Leine, and Ragnhild Stålesen in the Clinical Pharmacology Unit, and Kajsa Sundqvist in the Endocrinology &amp; Diabetology Unit, Karolinska University Hospital-Solna, for expert technical assistance, and Per Näsman, PhD, Royal Institute of Technology, Stockholm, for valuable statistical advice. The authors are grateful for the opportunity to use the collagen-related peptide CRP-18/I, which was kindly provided by Dr. Richard Farndale, Biochemistry, Cambridge University, U.K.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aryangat</surname><given-names>AV</given-names></name><name><surname>Gerich</surname><given-names>JE</given-names></name></person-group>
<article-title>Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk</article-title>. <source>Vasc Health Risk Manag</source>
<year>2010</year>;<volume>6</volume>:6<fpage>145</fpage>–<lpage>155</lpage><pub-id pub-id-type="pmid">20448799</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier</surname><given-names>L</given-names></name><name><surname>Mas</surname><given-names>E</given-names></name><name><surname>Ginet</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes</article-title>. <source>JAMA</source>
<year>2006</year>;<volume>295</volume>:<fpage>1681</fpage>–<lpage>1687</lpage><pub-id pub-id-type="pmid">16609090</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriello</surname><given-names>A</given-names></name><name><surname>Cavarape</surname><given-names>A</given-names></name><name><surname>Martinelli</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart</article-title>. <source>Diabet Med</source>
<year>2004</year>;<volume>21</volume>:<fpage>171</fpage>–<lpage>175</lpage><pub-id pub-id-type="pmid">14984453</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yngen</surname><given-names>M</given-names></name><name><surname>Östenson</surname><given-names>CG</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name><name><surname>Wallén</surname><given-names>NH</given-names></name></person-group>
<article-title>Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide</article-title>. <source>Diabet Med</source>
<year>2006</year>;<volume>23</volume>:<fpage>134</fpage>–<lpage>140</lpage><pub-id pub-id-type="pmid">16433710</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razmara</surname><given-names>M</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name><name><surname>Yngen</surname><given-names>M</given-names></name><name><surname>Ostenson</surname><given-names>CG</given-names></name><name><surname>Wallén</surname><given-names>NH</given-names></name><name><surname>Li</surname><given-names>N</given-names></name></person-group>
<article-title>Food intake enhances thromboxane receptor-mediated platelet activation in type 2 diabetic patients but not in healthy subjects</article-title>. <source>Diabetes Care</source>
<year>2007</year>;<volume>30</volume>:<fpage>138</fpage>–<lpage>140</lpage><pub-id pub-id-type="pmid">17192347</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santilli</surname><given-names>F</given-names></name><name><surname>Formoso</surname><given-names>G</given-names></name><name><surname>Sbraccia</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus</article-title>. <source>J Thromb Haemost</source>
<year>2010</year>;<volume>8</volume>:<fpage>828</fpage>–<lpage>837</lpage><pub-id pub-id-type="pmid">20088941</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woerle</surname><given-names>HJ</given-names></name><name><surname>Neumann</surname><given-names>C</given-names></name><name><surname>Zschau</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels</article-title>. <source>Diabetes Res Clin Pract</source>
<year>2007</year>;<volume>77</volume>:<fpage>280</fpage>–<lpage>285</lpage><pub-id pub-id-type="pmid">17240473</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Wallén</surname><given-names>NH</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name></person-group>
<article-title>Evidence for prothrombotic effects of exercise and limited protection by aspirin</article-title>. <source>Circulation</source>
<year>1999</year>;<volume>100</volume>:<fpage>1374</fpage>–<lpage>1379</lpage><pub-id pub-id-type="pmid">10500036</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Ekberg</surname><given-names>K</given-names></name><name><surname>Johansson</surname><given-names>B-L</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name></person-group>
<article-title>Insulin, but not proinsulin C-peptide, enhances platelet fibrinogen binding in vitro in Type 1 diabetes mellitus patients and healthy subjects</article-title>. <source>Thromb Res</source>
<year>2002</year>;<volume>106</volume>:<fpage>91</fpage>–<lpage>95</lpage><pub-id pub-id-type="pmid">12182905</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farndale</surname><given-names>RW</given-names></name><name><surname>Lisman</surname><given-names>T</given-names></name><name><surname>Bihan</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions</article-title>. <source>Biochem Soc Trans</source>
<year>2008</year>;<volume>36</volume>:<fpage>241</fpage>–<lpage>250</lpage><pub-id pub-id-type="pmid">18363567</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massucco</surname><given-names>P</given-names></name><name><surname>Mattiello</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism</article-title>. <source>Thromb Haemost</source>
<year>2005</year>;<volume>93</volume>:<fpage>517</fpage>–<lpage>526</lpage><pub-id pub-id-type="pmid">15735804</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudic</surname><given-names>D</given-names></name><name><surname>Razmara</surname><given-names>M</given-names></name><name><surname>Forslund</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>N</given-names></name></person-group>
<article-title>High glucose levels enhance platelet activation: involvement of multiple mechanisms</article-title>. <source>Br J Haematol</source>
<year>2006</year>;<volume>133</volume>:<fpage>315</fpage>–<lpage>322</lpage><pub-id pub-id-type="pmid">16643434</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajek</surname><given-names>AS</given-names></name><name><surname>Joist</surname><given-names>JH</given-names></name></person-group>
<article-title>Platelet insulin receptor</article-title>. <source>Methods Enzymol</source>
<year>1992</year>;<volume>215</volume>:<fpage>398</fpage>–<lpage>403</lpage><pub-id pub-id-type="pmid">1435335</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>IA</given-names></name><name><surname>Eybrechts</surname><given-names>KL</given-names></name><name><surname>Mocking</surname><given-names>AI</given-names></name><name><surname>Kroner</surname><given-names>C</given-names></name><name><surname>Akkerman</surname><given-names>JW</given-names></name></person-group>
<article-title>IRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein Gi</article-title>. <source>J Biol Chem</source>
<year>2004</year>;<volume>279</volume>:<fpage>3254</fpage>–<lpage>3264</lpage><pub-id pub-id-type="pmid">14602724</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>RW</given-names></name><name><surname>Hers</surname><given-names>I</given-names></name></person-group>
<article-title>Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function</article-title>. <source>J Thromb Haemost</source>
<year>2009</year>;<volume>7</volume>:<fpage>2123</fpage>–<lpage>2130</lpage><pub-id pub-id-type="pmid">19817984</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yngen</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Hjemdahl</surname><given-names>P</given-names></name><name><surname>Wallén</surname><given-names>NH</given-names></name></person-group>
<article-title>Insulin enhances platelet activation in vitro</article-title>. <source>Thromb Res</source>
<year>2001</year>;<volume>104</volume>:<fpage>85</fpage>–<lpage>91</lpage><pub-id pub-id-type="pmid">11672752</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anfossi</surname><given-names>G</given-names></name><name><surname>Massucco</surname><given-names>P</given-names></name><name><surname>Mattiello</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Insulin exerts opposite effects on platelet function at physiological and supraphysiological concentrations</article-title>. <source>Thromb Res</source>
<year>1996</year>;<volume>82</volume>:<fpage>57</fpage>–<lpage>68</lpage><pub-id pub-id-type="pmid">8731510</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>IA</given-names></name><name><surname>Mocking</surname><given-names>AIM</given-names></name><name><surname>Feijge</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Platelet inhibition by insulin is absent in type 2 diabetes mellitus</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<year>2006</year>;<volume>26</volume>:<fpage>417</fpage>–<lpage>422</lpage><pub-id pub-id-type="pmid">16339499</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murer</surname><given-names>EH</given-names></name><name><surname>Gyda</surname><given-names>MA</given-names></name><name><surname>Martinez</surname><given-names>NJ</given-names></name></person-group>
<article-title>Insulin increases the aggregation response of human platelets to ADP</article-title>. <source>Thromb Res</source>
<year>1994</year>;<volume>73</volume>:<fpage>69</fpage>–<lpage>74</lpage><pub-id pub-id-type="pmid">8178315</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauchfuss</surname><given-names>S</given-names></name><name><surname>Geiger</surname><given-names>J</given-names></name><name><surname>Walter</surname><given-names>U</given-names></name><name><surname>Renne</surname><given-names>T</given-names></name><name><surname>Gambaryan</surname><given-names>S</given-names></name></person-group>
<article-title>Insulin inhibition of platelet-endothelial interaction is mediated by insulin effects on endothelial cells without direct effects on platelets</article-title>. <source>J Thromb Haemost</source>
<year>2008</year>;<volume>6</volume>:<fpage>856</fpage>–<lpage>864</lpage><pub-id pub-id-type="pmid">18284601</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerbacka</surname><given-names>J</given-names></name><name><surname>Yki-Järvinen</surname><given-names>H</given-names></name><name><surname>Turpeinen</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity</article-title>. <source>Arterioscler Thromb Vasc Biol</source>
<year>2002</year>;<volume>22</volume>:<fpage>167</fpage>–<lpage>172</lpage><pub-id pub-id-type="pmid">11788478</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerrits</surname><given-names>AJ</given-names></name><name><surname>Koekman</surname><given-names>CA</given-names></name><name><surname>van Haeften</surname><given-names>TW</given-names></name><name><surname>Akkerman</surname><given-names>JW</given-names></name></person-group>
<article-title>Platelet tissue factor synthesis in type 2 diabetic patients is resistant to inhibition by insulin</article-title>. <source>Diabetes</source>
<year>2010</year>;<volume>59</volume>:<fpage>1487</fpage>–<lpage>1495</lpage><pub-id pub-id-type="pmid">20200314</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellbin</surname><given-names>LG</given-names></name><name><surname>Malmberg</surname><given-names>K</given-names></name><name><surname>Norhammar</surname><given-names>A</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Rydén</surname><given-names>L</given-names></name><collab>DIGAMI 2 Investigators</collab></person-group>
<article-title>The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial</article-title>. <source>Eur Heart J</source>
<year>2008</year>;<volume>29</volume>:<fpage>166</fpage>–<lpage>176</lpage><pub-id pub-id-type="pmid">18156614</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><name><surname>Bernardo</surname><given-names>E</given-names></name><name><surname>Ramírez</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment</article-title>. <source>J Am Coll Cardiol</source>
<year>2006</year>;<volume>48</volume>:<fpage>298</fpage>–<lpage>304</lpage><pub-id pub-id-type="pmid">16843179</pub-id></mixed-citation></ref></ref-list></back></article>